These data led Sweeney et al. to study the effect of a multi-kinase inhibitor of EGFR axis, c-Src and VEGFR, called tesevatinib (TSV), as a possible therapy in preclinical studies for ARPKD obtaining favorable results [175]. This evidence concerns the gene EGFR and autosomal recessive polycystic kidney disease.